NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Ingersoll Rand India Reports Muted Quarter Amidst Global Uncertainties

Ingersoll-Rand India (INGR) has released its latest research report, highlighting a decline in revenue and EBITDA margin for the quarter. The company's revenue decreased by 7% year-over-year (YoY) to Rs3.0 billion, while its EBITDA margin contracted by 285 basis points YoY to 23.0% due to higher other expenses.

MetricQoQYoY
Revenue (Rs billion)-7%-7%
EBITDA Margin (%)-285bps

The research report indicates that the underlying domestic demand for air compressors remains healthy across key industrial sectors. However, elongated customer decision-making cycles are continuing to delay order finalizations and revenue conversion. Furthermore, geopolitical uncertainties are posing near-term risks to export volumes to the parent, limiting visibility on external demand.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Despite these challenges, the newly commissioned Sanand facility is expected to support future growth and improve manufacturing flexibility. The company is also focusing on expanding its oil-free portfolio, increasing localization, and strengthening OEM and rental channels. These efforts are expected to support competitiveness and margin resilience over the medium term.

The stock is currently trading at a price-to-earnings ratio (PE) of 44.1x on FY27 estimates and 37.0x on FY28 estimates. The research report has revised its FY27E/FY28E earnings per share (EPS) estimates by -3.6%/-1.3% and downgraded its rating from 'BUY' to 'Accumulate'. The revised target price is Rs4,934, valuing the stock at a PE of 42x Mar'28E.

Investor Takeaway

Investors should be cautious about the muted quarter and near-term risks to export volumes.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.